PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
27307592-9	2016	At the molecular level, quinacrine and sorafenib inhibited expression of prosurvival MCL1, pSTAT3, and dampened NFkappaB signaling.	Sorafenib	39-48	myeloid cell leukemia sequence 1	Mus musculus	85-89	
31337603-8	2019	Elevated MCL-1 expression was present in sorafenib-resistant murine HCC cells, while MCL-1 knockdown sensitized these cells to sorafenib.	Sorafenib	41-50	myeloid cell leukemia sequence 1	Mus musculus	9-14	
22952216-7	2012	Mcl-1, a survival factor in multiple myeloma, is downregulated at the protein level by sorafenib allowing for the execution of cell death, as ectopic overexpression of this protein protects multiple myeloma cells.	Sorafenib	87-96	myeloid cell leukemia sequence 1	Mus musculus	0-5	
24852430-6	2014	Notably, Tiam1 siRNA or sorafenib alone obviously increased p27 level, but reduced Mcl-1 and bcl-2 levels in xenografted nude mice, and their combinations reached the best effect.	Sorafenib	24-33	myeloid cell leukemia sequence 1	Mus musculus	83-88	
22952216-8	2012	Concomitant targeting of Mcl-1 by sorafenib and of Bcl-2/Bcl-xL by the antagonist ABT737 improves the efficacy of sorafenib in multiple myeloma cell lines and CD138(+)-enriched primary cells in the presence of bone marrow stromal cells.	Sorafenib	114-123	myeloid cell leukemia sequence 1	Mus musculus	25-30	
23231952-8	2013	Sorafenib also blocks Mcl-1 and cyclin D1 translation, which promotes an imbalance between pro- and antiapoptotic proteins and facilitates Bax release from cyclin D1, leading to the induction of mitochondrial apoptosis and caspase-dependent and -independent mechanisms.	Sorafenib	0-9	myeloid cell leukemia sequence 1	Mus musculus	22-27	
22952216-8	2012	Concomitant targeting of Mcl-1 by sorafenib and of Bcl-2/Bcl-xL by the antagonist ABT737 improves the efficacy of sorafenib in multiple myeloma cell lines and CD138(+)-enriched primary cells in the presence of bone marrow stromal cells.	Sorafenib	34-43	myeloid cell leukemia sequence 1	Mus musculus	25-30	
20015197-6	2011	Sorafenib inhibited cell growth (IG(50) values ranged from 3.4 to 8.1 muM) and caused down-regulation of MAP-K/ERK phosphorylation and of mcl-1 and p-bad expression after a 48-hr exposure.	Sorafenib	0-9	myeloid cell leukemia sequence 1	Mus musculus	138-143	
22446485-7	2012	Finally, studies in a xenograft mouse model revealed that combined sorafenib/obatoclax treatment markedly reduced tumor growth and significantly prolonged survival in association with Mcl-1 down-regulation and apoptosis induction, whereas agents administered individually had only modest effects.	Sorafenib	67-76	myeloid cell leukemia sequence 1	Mus musculus	184-189	
22406995-9	2012	Sorafenib inhibited expression of cyclin E, cyclin D1/D2/D3, key regulators for cell cycle, and the antiapoptotic proteins Mcl-1 and survivin.	Sorafenib	0-9	myeloid cell leukemia sequence 1	Mus musculus	123-128	
20884624-8	2010	Our data showed that sorafenib downregulated phospho-STAT3 (pSTAT3) and subsequently reduced the expression levels of STAT3-related proteins (Mcl-1, survivin, and cyclin D1) in a dose- and time-dependent manner in TRAIL-treated HCC cells.	Sorafenib	21-30	myeloid cell leukemia sequence 1	Mus musculus	142-147	
17595328-6	2007	Ba/F3 cells expressing Bcr/Abl mutations were as sensitive to sorafenib-induced Mcl-1 down-regulation and dephosphorylation of STAT5 and eukaryotic initiation factor 4E as wild-type cells.	Sorafenib	62-71	myeloid cell leukemia sequence 1	Mus musculus	80-85